Back To TopGet Opthea Updates
John Han

John Han

Dr. Han’s career in biotechnology and pharmaceutical industry spans over 25 years, with 19 years in ophthalmology.  He brings experience in early and late-stage drug development in both anterior and posterior ophthalmology.    He has a...
Mark O’Neill

Mark O’Neill

Mark O’Neill was appointed Vice President CMC in January 2022.  Mr. O’Neill was most recently head of Process Development for Avexis Gene therapies where he orchestrated all product development and technical operations activities pertaining to the startup and...
Karen Adams

Karen Adams

Karen Adams was appointed Vice President Finance in May 2021 and Company Secretary in June 2021. Karen is accountable directly to the board, through the chair, on all matters to do with the proper functioning of Opthea’s board. Prior to joining Opthea, Karen was the...
Bruno Gagnon

Bruno Gagnon

Bruno joined Opthea in July 2022 and leads Global Clinical Operations. Bruno is former Sr. Vice President of Development Operations at Eidos Therapeutics, a BridgeBio company in San Francisco, CA. He also served as Vice President of Clinical Operations at BioMarin...
Fang Li

Fang Li

Dr. Li is an accomplished regulatory affairs professional with over three decades of experience in pharmaceutical development and regulatory affairs. She has held leadership positions at Novartis, Alcon, and Bausch & Lomb, where her contributions encompass health...